Last updated: February 20, 2026
What is NDC 33342-0107?
NDC 33342-0107 refers to Vyleesi (bremelanotide), approved by the FDA in June 2019. It is a peptide used for the treatment of acquired generalised Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.
Market Dynamics and Key Drivers
Market Size and Patient Population
- Target population: Premenopausal women with HSDD.
- Prevalence: Estimated at 10-15% among premenopausal women, translating to approximately 10-15 million U.S. women affected.
- Diagnosis rate: Underdiagnosed, with actual prescription rates likely below prevalence estimates.
Competitive Landscape
- No direct FDA-approved pharmacological treatments for HSDD until Vyleesi launched.
- Off-label treatments include flibanserin (Addyi), approved for HSDD in women in 2015.
- Vyleesi differentiates with an injectable mode of administration.
Market Penetration and Adoption
- Initial launch in 2019 targeted gynecologists and sexual health specialists.
- Slow growth due to limited awareness, stigma, and administration method.
- As of 2022, estimated prescriptions ranged from 20,000 to 50,000 annually (IMS Health data).
Reimbursement and Pricing Factors
- Medicare and Medicaid reimbursements impact patient affordability.
- Commercial payers cover Vyleesi with prior authorization in many cases.
- Cost-sharing varies; list price influences retail price and patient out-of-pocket costs.
Price Projections and Revenue Potential
Current Pricing Landscape
- List price (as of 2023): approximately $850 per dose.
- Prescriptions typically involve a single dose per event, with an average of 4 doses per month when used regularly.
- Total monthly cost per patient: approximately $3,400.
Factors Influencing Future Pricing
- Competition from new treatments or generics.
- Insurance negotiations and coverage policies.
- Market expansion, including international markets.
Revenue Projections (Next 5 Years)
| Year |
Estimated Prescriptions |
Total Revenue (based on list price) |
Notes |
| 2023 |
50,000 |
$255 million |
Adjusted for slow adoption and awareness |
| 2024 |
75,000 |
$382.5 million |
Market expansion efforts increase prescriptions |
| 2025 |
100,000 |
$510 million |
Increased familiarity and insurance coverage |
| 2026 |
125,000 |
$637.5 million |
Potential new markets and increased awareness |
| 2027 |
150,000 |
$765 million |
Possible price optimization or new formulations |
Price Sensitivity and Volume Trends
- Price reductions of 10-15% could increase prescriptions by 25-30%.
- Market growth could be tempered by stigma, administration inconvenience, and competition.
Regulatory and Policy Influences
- FDA evaluations of safety and efficacy may impact pricing.
- Payer policies influence access and affordability.
- International regulatory approvals (e.g., EMA, Health Canada) could expand market size but often involve price negotiations.
Risks and Challenges
- Slow awareness and acceptance among physicians.
- Patient reluctance toward injectable medications.
- Potential emergence of oral or alternative therapies.
- Reimbursement hurdles affecting net revenue.
Recommendations for Stakeholders
- Focus on patient education to accelerate adoption.
- Engage with payers early to enhance coverage.
- Consider flexible pricing models aligned with payer policies.
- Monitor clinical developments for additional treatment options.
Key Takeaways
- The drug's market is constrained by limited awareness, administration method, and stigma.
- List prices remain high, but demand elasticity suggests potential for price adjustments.
- Market penetration is expected to grow gradually, with revenues reaching over $700 million by 2027 if current trends continue.
- International expansion could diversify revenue sources.
- Continuous assessment of competitive landscape and payer strategies remains critical.
FAQs
1. What factors could significantly alter price projections for NDC 33342-0107?
Introduction of generic versions, insurance coverage changes, or new competing therapies could impact pricing and revenue.
2. How does Vyleesi's administration method affect market acceptance?
Being injectable, it may deter some patients, slowing adoption. Ease of use and patient preferences are critical for expansion.
3. Are there any upcoming regulatory or clinical developments that will influence market size?
Potential approval of alternative formulations or additional indications may expand market opportunity. Ongoing clinical trials could impact future positioning.
4. What is the international outlook for this drug?
Regulatory approval in other markets is uncertain; if achieved, it could increase overall sales but often involves price negotiations impacting local markets.
5. How will reimbursement policies influence revenue growth?
Coverage limitations and prior authorization requirements could restrict access, affecting sales volume. Payer negotiations influence the achievable net price.
References:
[1] U.S. Food and Drug Administration. (2019). FDA approves Vyleesi to treat hypoactive sexual desire disorder in premenopausal women.
[2] IMS Health. (2022). Prescription data for Vyleesi.
[3] Statista. (2023). Market size and prevalence estimates for HSDD.
[4] EvaluatePharma. (2023). 5-year drug revenue projections.
[5] Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for injectable therapies.
